The Global. If last week it was the general director of Kern Pharma, Manuel Garrido, who claimed, during the presentation of Remsima, that the biosimilar should not be used exclusively as a key to force the originals to lower their prices, since that would make it impossible development of this sector, this week it was Cinfa's Development Director, Julio Masset, who called for a stimulating policy for the national biosimilars industry.

READ MORE